Newsroom | 47263 results

LONDON--(BUSINESS WIRE)--Hanshow, a global leader in electronic shelf labels (ESL) and digital store solutions, has entered into a multi-year research collaboration with the University of Cambridge, one of the world’s most prestigious academic institutions. The partnership will focus on joint research and innovation in next-generation intelligent hybrid wireless technologies, marking an important milestone in Hanshow’s continued investment in core technologies and long-term innovation. This col...

DALLAS--(BUSINESS WIRE)--Generational Group, a leading mergers and acquisitions advisory firm for privately held businesses, is pleased to announce the sale of Farabaugh Engineering & Testing Inc. to Certerra. The acquisition closed August 15, 2025. Headquartered in McKeesport, Pennsylvania, Farabaugh Engineering & Testing Inc. (FETLabs) is a family-owned, full-service engineering laboratory with more than 35 years of experience in the building components industry. The company provides...

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced a definitive asset purchase agreement for Gilead Sciences, Inc. to acquire Repare’s polymerase theta (Polθ) ATPase inhibitor, RP-3467 (the “Gilead Agreement”). “We are pleased to announce this transaction which combines Gilead’s leading expertise in oncology research and development with RP-3467, a potential best-in-class...

ROCHESTER, Minn.--(BUSINESS WIRE)--Vyriad announced $25M final tranche of its Series B to support the first-in-human testing of VV169, Vyriad’s in vivo CAR-T candidate....

SAN DIEGO--(BUSINESS WIRE)--BioMed Realty (“Company”), the largest privately owned operator of real estate for the life science and technology industries in the United States and the United Kingdom, today released its 2024 Sustainability Report, demonstrating continued industry leadership in sustainable development, decarbonization, community partnership, and responsible business operations. The report showcases how BioMed Realty’s tenant-first and vertically integrated model consistently provi...

LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present at the J.P. Morgan 44th Annual Healthcare Conference in San Francisco. Vladimir Makatsaria, Chief Executive Officer of LivaNova, and Alex Shvartsburg, Chief Financial Officer, will participate in a fireside chat on Wed., Jan. 14, 2026, at 1:30 p.m. Pacific Standard Time. The discussion will be available to all interested parties who register to attend the webcast, w...

MADISON, Wis.--(BUSINESS WIRE)--Qolab closed 2025 with a series of strategic collaborations, product deployments, and industry leadership milestones that underscore growing momentum behind its approach to scalable superconducting quantum hardware. Together, these advances mark foundational progress toward the company’s mission to build a commercially useful quantum computer through semiconductor-aligned manufacturing and system-level integration. Throughout the year, Qolab deepened relationship...

BOULDER, Colo.--(BUSINESS WIRE)--Enveda, a multi-asset clinical-stage biotech company pioneering the discovery and development of a new generation of small-molecule drugs derived from life’s chemistry, today announced that the US Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for ENV-6946. Following this clearance, Enveda has initiated a Phase 1 clinical trial for ENV-6946, a first-in-class oral small molecule for the treatment of Inflamm...

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announces that Health Canada has accepted, without objection, the Clinical Trial Application (CTA) for COYA 302 for the treatment of amyotrophic lateral sclerosis (ALS). The CTA acceptance by Health Canada allows for activation of clinical sit...

ST. PETERSBURG, Fla.--(BUSINESS WIRE)--VOKA provides one-month free access to VOKA 3D Anatomy & Pathology, a high-precision 3D atlas for medical education and clinical professionals....